Polaroid Therapeutics, a biotech start-up based in Switzerland, is making significant progress in developing advanced antimicrobial therapies for the treatment of acute and chronic wounds. Their innovative polymer technology offers a breakthrough solution that effectively reduces bacterial bioburden without contributing to antimicrobial resistance (AMR), a major global public health concern.
AMR occurs when bacteria, viruses, fungi, and parasites adapt to antimicrobials, rendering them less effective over time. This issue is worsened by the misuse and overuse of antimicrobial agents. In 2019, AMR was responsible for 1.27 million deaths worldwide, according to the World Health Organization. Polaroid Therapeutics aims to combat this problem by creating safe and highly potent polymers that disrupt bacterial cells in a unique manner.
Drawing inspiration from the brand that revolutionized instant photography, Polaroid Therapeutics is dedicated to creating a more meaningful and human-centered world through cutting-edge technology and research. They actively seek collaborations with industry leaders in wound care to develop superior healthcare products and promote a patient-centric care system.
Chronic wounds affect 1-2% of the global population annually, and this number is expected to rise as the population continues to age. Effective strategies for managing chronic wounds are in high demand, in order to enhance patient care and optimize healthcare resources. Polaroid Therapeutics recognizes this opportunity to improve healthcare practices and contribute to a more efficient and sustainable global healthcare system.
The global Advanced Wound Dressing (AWD) market was valued at $4.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030. Antimicrobial products account for a quarter of this market, driven by technological advancements, surgical procedures, and the increasing prevalence of chronic wounds. Polaroid Therapeutics and its partners are well-positioned to capitalize on this market growth by focusing on product development that prioritizes patient outcomes.
Ran Frenkel, CEO and Co-Founder of Polaroid Therapeutics, emphasizes their commitment to addressing the unmet medical needs of patients and providing effective solutions for chronic wound care on a global scale. Their innovative technologies have the potential to alleviate suffering and improve overall quality of care.
Founded in 2022, Polaroid Therapeutics continues to develop antimicrobial therapies based on their proprietary antibacterial technology. With unwavering vision and dedication to finding solutions that do not contribute to AMR, they are poised to revolutionize wound care and make a significant impact on global health.
Contact:
Abigail Carrigan
[email protected]
[Watch the Video](https://www.youtube.com/embed/q7NgnJm-El8)
The source of the article is from the blog girabetim.com.br